Search

Displaying results 9741 - 9750 of 10000 in total
  1. Drug

    Roxifiban

    go.drugbank.com/drugs/DB21089
    Experimental

    The usage of the INN stem '-fiban' in the name indicates that Roxifiban is a fibrinogen receptor antagonist (glycoprotein IIb/IIIa receptor antagonist).

    Categories: Platelet Glycoprotein GPIIb-IIIa Complex, antagonists & inhibitors
  2. Drug

    Sibrafiban

    go.drugbank.com/drugs/DB21420
    Experimental

    The usage of the INN stem '-fiban' in the name indicates that Sibrafiban is a fibrinogen receptor antagonist (glycoprotein IIb/IIIa receptor antagonist).

    Categories: Platelet Glycoprotein GPIIb-IIIa Complex, antagonists & inhibitors
  3. Drug

    Zerencotrep

    go.drugbank.com/drugs/DB21710
    Experimental

    The usage of the INN stem '-cotrep' in the name indicates that Zerencotrep is a transient receptor potential canonical channel 5 (TRPC5) antagonist.

  4. Drug

    Tonabersat

    go.drugbank.com/drugs/DB06578
    Investigational

  5. Drug

    ALS-08

    go.drugbank.com/drugs/DB05705
    Experimental

    ALS-08 is a proprietary creatine-derivative that is being developed as a potential therapeutic for amyotrophic lateral sclerosis (ALS). It is being developed by Avicena Group, Inc.

  6. Drug

    LLL-3348

    go.drugbank.com/drugs/DB05771
    Experimental

    The botanical drug product LLL-3348 is a once-daily oral formulation for treatment of chronic stable plaque type psoriasis.

    Categories: Complex Mixtures
  7. Drug

    Contulakin-G

    go.drugbank.com/drugs/DB05950
    Experimental

    Contulakin-G is a broad spectrum non-opioid analgesic. It is the synthetic form of a natural peptide extracted from the venom of the Conus Geographus sea snail.

  8. Drug

    CRA-028129

    go.drugbank.com/drugs/DB05951
    Experimental

    CRA-028129 is cathepsin S inhibitor which is under investigation for the treatment of psoriasis.

  9. Drug

    FG-2216

    go.drugbank.com/drugs/DB08687
    Investigational

    A orally active prolyl-hydroxylase inhibitor which can stabilize hypoxia-inducible transcription factor independent of oxygen availability.

    Synonyms: 1-Chloro-N- (hydroxyformylmethyl-4-hydroxyisoquinoline-3-carboxamide, 1-Chloro-N-(hydroxyformylmethyl-4-hydroxyisoquinoline-3-carboxamide
  10. Drug

    KBP-COVID-19

    go.drugbank.com/drugs/DB15858
    Investigational

    Upon harvest, the antigens were purified, and these components underwent preclinical testing in animals. … As of July 2020, KBP is conducting a Phase 1/2 clinical trial to evaluate the safety and immunogenicity of KBP-COVID-19 vaccine in healthy patients (NCT04473690).